CARDIOVASCULAR OUTCOMES AT RECOMMENDED BLOOD PRESSURE TARGETS IN MIDDLE AGED AND ELDERLY PATIENTS WITH TYPE 2 DIABETES MELLITUS AND HYPERTENSION

作者
Eirik Olsen,Björn Holzhauer,Stevo Julius,Sverre Erik Kjeldsen,Anne Cecilie K. Larstorp,Giuseppe Mancia,Maria H. Mehlum,Rune Mo,Morten Rostrup,Camilla Lund Søraas,Dion Zappe,Michael A. Weber
出处
期刊:Journal of Hypertension [Lippincott Williams & Wilkins]
卷期号:39 (Supplement 1): e395-e395
标识
DOI:10.1097/01.hjh.0000749148.94458.0c
摘要

Objective: The optimal blood pressure (BP) target for patients with type-2 diabetes mellitus (DM) and hypertension has been set at < 130/80 mmHg in guidelines. However, available data of event-based clinical outcomes trials show that little evidence supports these guideline recommendations. Design and method: We addressed this issue by post-hoc analyzing the risk of cardiovascular (CV) events in mostly elderly high-risk hypertensive patients with type-2 DM participating in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial. Patients (n = 5250) were divided into 4 groups according to the proportion of on-treatment visits before the occurrence of an event (< 25%, 25%-49%, 50–74%, 75% -100%) in which BP was reduced to < 140/90 or < 130/80 mmHg. Results: After adjustment for baseline demographic differences between groups, a reduction in the proportion of visits in which BP achieved < 140/90 mmHg accompanied a progressive increase in the risk of CV mortality and morbidity as well as of cause-specific events such as stroke, myocardial infarction and heart failure (Figure, upper panel). A progressive reduction in the proportion of visits in which BP was reduced < 130/80 mmHg did not have any effect on CV risks (Figure, lower panel). Conclusions: In mostly elderly high-risk hypertensive patients with type-2 diabetes mellitus participating in the VALUE trial, achieving more frequently BP < 140/90 mmHg showed a marked protective effect on overall and all cause specific cardiovascular outcomes. This was not the case for a more frequent achievement of the more intensive BP target, i.e. < 130/80 mmHg.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
宗剑完成签到,获得积分10
刚刚
YouY0123完成签到,获得积分10
1秒前
士兵许三多完成签到,获得积分10
1秒前
yibo完成签到,获得积分10
2秒前
月月完成签到,获得积分10
2秒前
巧克力手印完成签到,获得积分10
2秒前
alamo完成签到,获得积分10
2秒前
可靠的正豪完成签到,获得积分10
2秒前
echo完成签到,获得积分10
3秒前
你说得对发布了新的文献求助20
5秒前
米饭区完成签到 ,获得积分10
6秒前
haissem完成签到 ,获得积分10
6秒前
7秒前
sjw525完成签到,获得积分10
7秒前
BAEK完成签到 ,获得积分10
8秒前
8秒前
追寻的山晴完成签到,获得积分10
9秒前
852的应助被yy采纳,获得10
9秒前
ppp发布了新的文献求助10
11秒前
胜似闲庭信步完成签到,获得积分10
11秒前
Liii完成签到 ,获得积分10
11秒前
wei发布了新的文献求助10
12秒前
尊敬的驳完成签到,获得积分10
12秒前
JoJo完成签到,获得积分10
14秒前
star完成签到,获得积分10
17秒前
17秒前
小贾完成签到,获得积分10
18秒前
杀死周一完成签到,获得积分10
20秒前
tina酱完成签到 ,获得积分10
22秒前
zhangyiyang完成签到 ,获得积分10
22秒前
隐形骁完成签到,获得积分10
22秒前
23秒前
16601107082发布了新的文献求助10
24秒前
liuchang完成签到 ,获得积分10
24秒前
22336完成签到,获得积分0
24秒前
Lemenchichi完成签到,获得积分10
24秒前
老实的鑫磊完成签到,获得积分20
25秒前
会过期的凤梨完成签到 ,获得积分10
26秒前
hahaha完成签到 ,获得积分10
26秒前
wailwq完成签到 ,获得积分10
27秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8166570
求助须知:如何正确求助?哪些是违规求助? 9559581
关于积分的说明 21750904
捐赠科研通 7757397
什么是DOI,文献DOI怎么找? 3429170
关于科研通互助平台的介绍 2553530
邀请新用户注册赠送积分活动 2473923